BioCryst Pharmaceuticals Reports Leadership Changes
Ticker: BCRX · Form: 8-K · Filed: Aug 11, 2025 · CIK: 882796
Sentiment: neutral
Topics: leadership-change, board-election, compensation
Related Tickers: BCRX
TL;DR
BioCryst execs are changing, new directors elected, and pay packages adjusted.
AI Summary
BioCryst Pharmaceuticals, Inc. filed an 8-K on August 11, 2025, reporting on the departure of directors or certain officers, the election of directors, and compensatory arrangements for certain officers. The filing indicates changes within the company's leadership and executive compensation structure.
Why It Matters
Changes in corporate leadership and executive compensation can signal shifts in company strategy or financial priorities, potentially impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in executive and director roles, along with adjustments to compensation, can introduce uncertainty regarding future company direction and performance.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- August 11, 2025 (date) — Date of Report
FAQ
Who has departed from BioCryst Pharmaceuticals, Inc.?
The filing indicates the departure of directors or certain officers, but specific names are not provided in this excerpt.
Were new directors elected to BioCryst Pharmaceuticals, Inc.'s board?
Yes, the filing explicitly states the election of directors as an item of information.
What is the primary purpose of this 8-K filing for BioCryst Pharmaceuticals, Inc.?
The primary purpose is to report on the departure of directors or certain officers, the election of directors, and compensatory arrangements of certain officers.
When was this 8-K filing submitted by BioCryst Pharmaceuticals, Inc.?
The filing was submitted on August 11, 2025.
What is BioCryst Pharmaceuticals, Inc.'s principal executive office address?
The principal executive offices are located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
Filing Stats: 647 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2025-08-11 07:10:53
Key Financial Figures
- $12,500 — receive (i) a monthly consulting fee of $12,500, (ii) continued vesting of outstanding
Filing Documents
- f8k_081125.htm (8-K) — 22KB
- 0001171843-25-005265.txt ( ) — 183KB
- bcrx-20250811.xsd (EX-101.SCH) — 3KB
- bcrx-20250811_lab.xml (EX-101.LAB) — 33KB
- bcrx-20250811_pre.xml (EX-101.PRE) — 22KB
- f8k_081125_htm.xml (XML) — 4KB
02. Departure of Directors or Certain Officers; Election of Directors; Appointment
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 6, 2025, Dr. Helen Thackray, Chief Research and Development Officer of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the "Company"), notified the Company of her intention to resign from her role as Chief Research and Development Officer of the Company, effective September 1, 2025 (the "Effective Date"). After participating in the CEO accelerator program and not being selected as the Company's next CEO, Dr. Thackray has decided to pursue new opportunities. Dr. Thackray cited no disagreement with the Board of Directors (the "Board") or management relating to the Company, its operations, policies, or practices. In connection with her separation, the Company and Dr. Thackray entered into a Separation Agreement, pursuant to which Dr. Thackray will receive the following separation benefits in exchange for a general release of claims in favor of the Company: (i) one year of continued base salary, (ii) payment of her 2025 annual incentive plan bonus based on actual performance, (iii) payment of her target 2025 annual incentive plan bonus, (iv) up to 12 months of Company-paid group health plan continuation coverage, (v) up to six months of outplacement services, and (vi) accelerated vesting of her outstanding equity awards scheduled to vest in 2026. On August 7, 2025, the Compensation Committee of the Board also approved a Consulting Agreement with Dr. Thackray, effective as of the Effective Date, pursuant to which Dr. Thackray will provide transition services until December 31, 2025. Under the Consulting Agreement, Dr. Thackray will receive (i) a monthly consulting fee of $12,500, (ii) continued vesting of outstanding equity awards for the duration of the Consulting Agreement, and (iii) continued exercisability of her vested options until the date that is six months following the termination of